Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial

Clinical Nutrition

Volumn 35, Issue 3, 2016, Pages 578-586

  Nogueira, Monize Aydar ^a   Oliveira, Claudia Pinto ^a   Ferreira Alves, Venâncio Avancini ^a   Stefano, José Tadeu ^a   Rodrigues, Lívia Samara dos Reis ^a   Torrinhas, Raquel Susana ^a   Cogliati, Bruno ^a   Barbeiro, Hermes ^a   Carrilho, Flair José ^a   Waitzberg, Dan Linetzky ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alpha linolenic acid; Docosahexaenoic acid; Eicosapentaenoic acid; Fish oil; Flaxseed oil; Nonalcoholic steatohepatitis

Indexed keywords

DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; LINOLENIC ACID; LINSEED OIL; MINERAL OIL; OMEGA 3 FATTY ACID; PLACEBO; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE ACTIVITY SCORE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LIPID METABOLISM; LIVER BIOPSY; LIVER FUNCTION; MALE; NONALCOHOLIC FATTY LIVER; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; BIOPSY; BLOOD; BRAZIL; COMPARATIVE STUDY; DIET THERAPY; DIETARY SUPPLEMENT; FOLLOW UP; HYPERTRIGLYCERIDEMIA; IMMUNOLOGY; LIVER; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT DROPOUT; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; TEACHING HOSPITAL;

BIOMARKERS; BIOPSY; BRAZIL; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; FEMALE; FISH OILS; HOSPITALS, TEACHING; HUMANS; HYPERTRIGLYCERIDEMIA; LINSEED OIL; LIVER; LOST TO FOLLOW-UP; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATIENT COMPLIANCE; PATIENT DROPOUTS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 84930268665     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2015.05.001     Document Type: Article

References (32)

1. Adams L.A., Sanderson S., Lindor K.D., Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005, 42:132-138.
2. McClain C.J., Mokshagundam S.P., Barve S.S., Song Z., Hill D.B., Chen T., et al. Mechanisms of non-alcoholic steatohepatitis. Alcohol 2004, 34:67-79.
3. Berlanga A., Guiu-Jurado E., Porras J.A., Auguet T. Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol 2014, 7:221-239. 10.2147/CEG.S62831.
4. Zelber-Sagi S., Ratziu V., Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol 2011, 17:3377-3389. 10.3748/wjg.v17.i29.3377.
5. Araya J., Rodrigo R., Videla L.A., Thielemann L., Orellana M., Pettinelli P., et al. Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004, 106:635-643.
6. Masterton G.S., Plevris J.N., Hayes P.C. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2010, 31:679-692. 10.1111/j.1365-2036.2010.04230.x.
7. Scorletti E., Byrne C.D. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu Rev Nutr 2013, 33:231-248. 10.1146/annurev-nutr-071812-161230.
8. Harper C.R., Edwards M.J., DeFilippis A.P., Jacobson T.A. Flaxseed oil increases the plasma concentrations of cardioprotective (n-3) fatty acids in humans. J Nutr 2006, 136:83-87.
9. Wu H., Pan A., Yu Z., Qi Q., Lu L., Zhang G., et al. Lifestyle counseling and supplementation with flaxseed or walnuts influence the management of metabolic syndrome. J Nutr 2010, 140:1937-1942. 10.3945/jn.110.126300.
10. Pan A., Sun J., Chen Y., Ye X., Li H., Yu Z., et al. Effects of a flaxseed-derived lignan supplement in type 2 diabetic patients: a randomized, double-blind, cross-over trial. PLoS One 2007, 2. e1148.
11. Bloedon L.T., Balikai S., Chittams J., Cunnane S.C., Berlin J.A., Rader D.J., et al. Flaxseed and cardiovascular risk factors: results from a double blind, randomized, controlled clinical trial. J Am Coll Nutr 2008, 27:65-74.
12. Fukumitsu S., Villareal M.O., Onaga S., Aida K., Han J., Isoda H. α-Linolenic acid suppresses cholesterol and triacylglycerol biosynthesis pathway by suppressing SREBP-2, SREBP-1a and -1c expression. Cytotechnology 2013, 65:899-907. 10.1007/s10616-012-9510-x.
13. Alwayn I.P., Andersson C., Zauscher B., Gura K., Nosé V., Puder M. Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor. Transplantation 2005, 79:606-608.
14. Capanni M., Calella F., Biagini M.R., Genise S., Raimondi L., Bedogni G., et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006, 23:1143-1151.
15. Tanaka N., Sano K., Horiuchi A., Tanaka E., Kiyosawa K., Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 2008, 42:413-418. 10.1097/MCG.0b013e31815591aa.
16. Spadaro L., Magliocco O., Spampinato D., Piro S., Oliveri C., Alagona C., et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 2008, 40:194-199.
17. Sanyal A.J., Abdelmalek M.F., Suzuki A., Cummings O.W., Chojkier M. EPE-A study group. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 2014, 147:377-384. 10.1053/j.gastro.2014.04.046.
18. Zhu F.S., Liu S., Chen X.M., Huang Z.G., Zhang D.W. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 2008, 14:6395-6400.
19. Nobili V., Alisi A., Della Corte C., Risé P., Galli C., Agostoni C. Bedogni G.Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr Metab Cardiovasc Dis 2013, 23:1066-1070. 10.1016/j.numecd.2012.10.010.
20. Shirai N., Suzuki H., Wada S. Direct methylation from mouse plasma and from liver and brain homogenates. Anal Biochem 2005, 343:48-53.
21. Iverson S.J. Comparison of the bligh and dyer and folch methods for full lipid determination in a broad range of marine tissue. Lipids 2001, 36:1283-1287.
22. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Nonalcoholic steatohepatitis clinical research network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
23. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
24. de Miranda Torrinhas R.S., Santana R., Garcia T., Cury-Boaventura M.F., Sales M.M., Curi R., et al. Parenteral fish oil as a pharmacological agent to modulate post-operative immune response: a randomized, double-blind, and controlled clinical trial in patients with gastrointestinal cancer. Clin Nutr 2013, 32:503-510. 10.1016/j.clnu.2012.12.008.
25. Lean M.E., Han T.S., Morrison C.E. Waist circumference as a measure for indicating need for weight management. BMJ 1995, 311:158-161.
26. National Cholesterol Education Program High blood cholesterol ATP III guidelines at-a-glance quick desk reference U.S. Department of health and human services, public health service, national Institutes of health, national heart, lung, and blood institute May 2001, NIH Publication No. 01-3305.
27. Scorletti E., Bhatia L., McCormick K.G., Clough G.F., Nash K., Hodson L., et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the welcome study. Hepatology 2014, 60:1211-1221. WELCOME Study.
28. Argo C.K., Patrie J.T., Lackner C., Henry T.D., de Lange E.E., Weltman A.L., et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol 2015, 62:190-197. Article 28. 10.1016/j.jhep.2014.08.036.
29. Dasarathy S., Dasarathy J., Khiyami A., Yerian L., Hawkins C., Sargent R., et al. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2015, 49:137-144. Article 29. 10.1097/MCG.0000000000000099.
30. Parker H.M., Johnson N.A., Burdon C.A., Cohn J.S., O'Connor H.T., George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012, 56:944-951. 10.1016/j.jhep.2011.08.018.
31. Dewell A., Marvasti F.F., Harris W.S., Tsao P., Gardner C.D. Low- and high-dose plant and marine (n-3) fatty acids do not affect plasma inflammatory markers in adults with metabolic syndrome. J Nutr 2011, 141:2166-2171. 10.3945/jn.111.142240.
32. Janczyk W., Socha P., Lebensztejn D., Wierzbicka A., Mazur A., Neuhoff-Murawska J., et al. Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial. BMC Pediatr 2013, 23:85. 10.1186/1471-2431-13-85.